Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
- PMID: 16998485
- DOI: 10.1038/nm1475
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
Abstract
Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4(+) and CD8(+) T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.
Similar articles
-
A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.Hum Gene Ther. 2000 Jul 1;11(10):1453-63. doi: 10.1089/10430340050057521. Hum Gene Ther. 2000. PMID: 10910142 Clinical Trial.
-
Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.J Immunother. 2007 Jul-Aug;30(5):544-56. doi: 10.1097/CJI.0b013e3180335b7a. J Immunother. 2007. PMID: 17589295
-
Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.J Immunother. 2011 Apr;34(3):307-19. doi: 10.1097/CJI.0b013e318213cb90. J Immunother. 2011. PMID: 21389867
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.Blood. 2009 Aug 27;114(9):1958-67. doi: 10.1182/blood-2009-03-213256. Epub 2009 May 14. Blood. 2009. PMID: 19443656 Free PMC article.
-
The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.Eur J Cell Biol. 2012 Jan;91(1):31-5. doi: 10.1016/j.ejcb.2011.01.007. Epub 2011 Apr 1. Eur J Cell Biol. 2012. PMID: 21458882 Review.
Cited by
-
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8. Narra J. 2022. PMID: 38449903 Free PMC article. Review.
-
Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.Front Immunol. 2024 Jan 11;14:1290059. doi: 10.3389/fimmu.2023.1290059. eCollection 2023. Front Immunol. 2024. PMID: 38274824 Free PMC article. Review.
-
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature.Front Immunol. 2023 Dec 22;14:1287456. doi: 10.3389/fimmu.2023.1287456. eCollection 2023. Front Immunol. 2023. PMID: 38187387 Free PMC article. Review.
-
EBV-induced T-cell responses in EBV-specific and nonspecific cancers.Front Immunol. 2023 Sep 29;14:1250946. doi: 10.3389/fimmu.2023.1250946. eCollection 2023. Front Immunol. 2023. PMID: 37841280 Free PMC article. Review.
-
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.Curr Oncol. 2023 Sep 15;30(9):8501-8549. doi: 10.3390/curroncol30090619. Curr Oncol. 2023. PMID: 37754534 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
